Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cellsin vitro

Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas

(2015) Raúl M. Luque et al.   CANCER LETTERS

Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data

(2015) Susan L. Samson   NEUROENDOCRINOLOGY

In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features

(2015) Alejandro Ibáñez-Costa et al.   Scientific Reports

Somatotropinomas, But Not Nonfunctioning Pituitary Adenomas, Maintain a Functional Apoptotic RET/Pit1/ARF/p53 Pathway That Is Blocked by Excess GDNF

(2014) Esther Diaz-Rodriguez et al.   ENDOCRINOLOGY

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

(2014) A. Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Somatostatin analogs: does pharmacology impact antitumor efficacy?

(2014) Mounira Chalabi et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

(2014) Mônica R Gadelha et al.   Lancet Diabetes & Endocrinology

Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide

(2014) Baldomero Gonzalez et al.   Endocrinologia y Nutricion

Somatostatin receptors: From signaling to clinical practice

(2013) Marily Theodoropoulou et al.   FRONTIERS IN NEUROENDOCRINOLOGY

Preoperative Normalization of Cortisol Levels in Cushing's Disease After Medical Treatment: Consequences for Somatostatin and Dopamine Receptor Subtype Expression and In Vitro Response to Somatostatin Analogs and Dopamine Agonists

(2013) R. van der Pas et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Cellular and Molecular Basis for the Selective Desmopressin-Induced ACTH Release in Cushing Disease Patients: Key Role of AVPR1b Receptor and Potential Therapeutic Implications

(2013) R. M. Luque et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression

(2012) S. Tuvia et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly

(2012) Federico Gatto et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insights into the regulation of protein abundance from proteomic and transcriptomic analyses

(2012) Christine Vogel et al.   NATURE REVIEWS GENETICS

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers

(2012) Georg Golor et al.   Drug Design Development and Therapy

Resistance to Somatostatin Analogs in Acromegaly

(2011) Annamaria Colao et al.   ENDOCRINE REVIEWS

Medical treatment of prolactinomas

(2011) Annamaria Colao et al.   Nature Reviews Endocrinology

Pathogenesis of pituitary tumors

(2011) Shlomo Melmed   Nature Reviews Endocrinology

Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case–control study

(2011) Alessandra Fusco et al.   Pituitary

Pituitary tumours: The sst/D2 receptors as molecular targets

(2010) Leo J. Hofland et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Role of Somatostatin Receptors in Normal and Tumoral Pituitary Corticotropic Cells

(2010) Leo J. Hofland et al.   NEUROENDOCRINOLOGY

Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly

(2009) Leonardo Vieira Neto et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Identification and Characterization of Two Novel Truncated but Functional Isoforms of the Somatostatin Receptor Subtype 5 Differentially Present in Pituitary Tumors

(2009) Mario Durán-Prado et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma

(2009) Alessandra Fusco et al.   Pituitary

Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR

(2008) Giselle F Taboada et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas

(2008) Alessandra Fusco et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Rab18 Is Reduced in Pituitary Tumors Causing Acromegaly and Its Overexpression Reverts Growth Hormone Hypersecretion

(2008) Rafael Vazquez-Martinez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Somatostatin Analogs on a Growth Hormone-Releasing Hormone Secreting Bronchial Carcinoid,in Vivoandin VitroStudies

(2008) M. van Hoek et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial

(2008) M. Boscaro et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Selective agonism in somatostatin receptor signaling and regulation

(2007) Agnes Schonbrunn   MOLECULAR AND CELLULAR ENDOCRINOLOGY